Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Gilead Files Truvada for HIV Prevention in Japan
Gilead Sciences said on February 28 that it has filed a public knowledge-based application for Truvada (emtricitabine + tenofovir disoproxil fumarate) for an additional indication of pre-exposure prophylaxis (PrEP) against HIV-1 infection. In Japan, the drug was approved in March…
To read the full story
Related Article
- Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
April 17, 2025
- Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
- Takeda’s Fruzaqla in Line for Approval, Broader Labels for Truvada, Keytruda, Prevenar 20 Too
August 5, 2024
- Truvada Clears Preliminary Review for PrEP Use, but Coverage Not Granted
February 6, 2024
- Will Truvada Win Health Coverage as Japan’s First Drug for HIV Prevention?
February 5, 2024
- Council OKs Public-Knowledge Application for Truvada Use as PrEP for HIV
December 1, 2023
- HIV Groups Pin Hopes on MHLW’s Development Requests for Preventive Therapy
September 4, 2023
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
BUSINESS
- GenAI Use at Japan Pharmas Rises to 92% in 2026: Funlead Survey
September 24, 2026
- FDA Accepts Tanabe’s EPP/XLP Drug for Priority Review
September 24, 2026
- Moderna Launches XFG-Updated mNEXSPIKE in Japan
September 24, 2026
- Japan OKs FoundationOne CDx for Pfizer’s Lorbrena
September 24, 2026
- Takeda Commits US$22.2 Million to Climate-Resilient Health Systemss
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…